Cross-Species-Specific Pscaxcd3, Cd19Xcd3, C-Metxcd3, Endosialinxcd3, Epcamxc D3, Igf-1Rxcd3 Or Fapalpha Xcd3 Bispecific Single Chain Antibody

Patent No. EP2370467 (titled "Cross-Species-Specific Pscaxcd3, Cd19Xcd3, C-Metxcd3, Endosialinxcd3, Epcamxc D3, Igf-1Rxcd3 Or Fapalpha Xcd3 Bispecific Single Chain Antibody") was filed by Amgen Research Munich on Oct 1, 2009. The application was issued on Sep 7, 2016.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JANSSEN BIOTECHJun 7, 2017CARPMAELS & RANSFORD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2370467

AMGEN RESEARCH MUNICH
Application Number
EP09740078A
Filing Date
Oct 1, 2009
Status
Granted And Under Opposition
Publication Date
Sep 7, 2016